We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

110 hedge funds and large institutions have $98.2M invested in iShares US Pharmaceuticals ETF in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

9% more funds holding

Funds holding: 101 → 110 (+9)

0.95% more ownership

Funds ownership: 77.5% → 78.45% (+0.95%)

0% less capital invested

Capital invested by funds: $98.4M → $98.2M (-$139K)

12% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 26

Holders
110
Holders Change
+9
Holders Change %
+8.91%
% of All Funds
1.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
23
Reduced
26
Closed
5
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
Osaic Holdings
Osaic Holdings
Arizona
+$1.72M
2
FTUS
Flow Traders U.S.
New York
+$939K
3
IWC
Integrated Wealth Concepts
Massachusetts
+$884K
4
AWM
AE Wealth Management
Kansas
+$669K
5
Morgan Stanley
Morgan Stanley
New York
+$354K

Top Sellers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$2.37M
2
UBS Group
UBS Group
Switzerland
-$2.21M
3
Bank of America
Bank of America
North Carolina
-$991K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$228K
5
AFG
Arkansas Financial Group
Arkansas
-$202K
Name Holding Trade Value Shares
Change 		Change in
Stake
AMG
26
Asset Management Group
Connecticut
$728K – – –
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$679K -$228K -3,585 -24%
AWM
28
AE Wealth Management
Kansas
$643K +$669K +10,530 New
RJFSA
29
Raymond James Financial Services Advisors
Florida
$636K -$40.6K -639 -6%
Goldman Sachs
30
Goldman Sachs
New York
$556K – – –
Rockefeller Capital Management
31
Rockefeller Capital Management
New York
$517K -$6.1K -96 -1%
OPS
32
Orion Portfolio Solutions
Nebraska
$507K -$15.1K -237 -3%
JMPWA
33
JP Morgan Private Wealth Advisors
California
$446K +$191 +3 +0%
OC
34
Oppenheimer & Co
New York
$394K – – –
CAN
35
Cetera Advisor Networks
California
$392K -$11.8K -186 -3%
JP Morgan Chase
36
JP Morgan Chase
New York
$362K +$1.91K +30 +0.5%
RMAM
37
Raab & Moskowitz Asset Management
New Jersey
$329K – – –
KAS
38
Kestra Advisory Services
Texas
$329K +$88.1K +1,386 +35%
Bank of Montreal
39
Bank of Montreal
Ontario, Canada
$314K -$57.2K -900 -16%
CA
40
Cetera Advisors
Colorado
$312K +$325K +5,106 New
Ameriprise
41
Ameriprise
Minnesota
$311K +$6.29K +99 +2%
RWA
42
Roberts Wealth Advisors
California
$301K +$314K +4,938 New
Cambridge Investment Research Advisors
43
Cambridge Investment Research Advisors
Iowa
$294K +$42.3K +666 +16%
Fidelity Investments
44
Fidelity Investments
Massachusetts
$291K – – –
BAM
45
Belpointe Asset Management
Nevada
$287K +$11.8K +186 +4%
IFWM
46
Institute for Wealth Management
Colorado
$283K +$295K +4,644 New
ASN
47
Advisory Services Network
Georgia
$277K – – –
Cetera Investment Advisers
48
Cetera Investment Advisers
Illinois
$264K -$67.1K -1,056 -20%
WI
49
Wintrust Investments
Illinois
$258K +$269K +4,233 New
NFC
50
Northeast Financial Consultants
Connecticut
$253K – – –
1
2
3 4 5

IHE Hedge Fund Activity: Q3 2021 in Review

110 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2021, worth a combined $98.2M — down 0.14% from $98.4M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new IHE positions and 5 closed out — a net gain of 9 holders — while 23 added to existing stakes and 26 trimmed.

The largest buyer was Osaic Holdings, adding an estimated $1.72M. The largest seller was Royal Bank of Canada, cutting an estimated $2.37M.

  • 110 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2021, up from 101 in Q2 2021.
  • Funds reported $98.2M of iShares US Pharmaceuticals ETF stock for Q3 2021, down 0.14% quarter-over-quarter.
  • 14 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2021 and 5 closed out, a net change of +9 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2021 was Osaic Holdings, an estimated $1.72M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2021 was Royal Bank of Canada, an estimated $2.37M sold.

Based on aggregated 13F filings for Q3 2021.